Anti-DBH-SAP is a highly specific noradrenergic lesioning agent. It specifically targets cells that express DBH. This vesicular enzyme is exposed to the exterior milieu upon release of noradrenaline and thus allows these cells to be targeted with saporin. The specificity of Anti-DBH-SAP correlates well with uptake of the antibody when injected intraventricularly. After systemic administration, animals have a massive reduction in plasma norepinephrine levels, indicating efficient targeting and sympathectomy. Unlike other lesioning methods, this molecular lesioning agent assures definitive ablation of the target neurons expressing rat DBH. Permanent and selective removal of cerebral noradrenergic innervation makes an important animal model for the study of drug effects (anti-hypertensives, opiates, stimulants, etc.), behavior (fear, depression, food intake), plasticity of other systems in response to loss, and primary autonomic failure.
Anti-DBH-SAP is a chemical conjugate of the mouse monoclonal antibody to dopamine beta-hydroxylase and the ribosome-inactivating protein, saporin. It specifically eliminates cells that express dopamine beta-hydroxylase.